These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 31646432)

  • 1. Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis.
    Konnopka A; König H
    Pharmacoeconomics; 2020 Jan; 38(1):25-37. PubMed ID: 31646432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The global economic burden of COVID-19 disease: a comprehensive systematic review and meta-analysis.
    Faramarzi A; Norouzi S; Dehdarirad H; Aghlmand S; Yusefzadeh H; Javan-Noughabi J
    Syst Rev; 2024 Feb; 13(1):68. PubMed ID: 38365735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The excess costs of depression: a systematic review and meta-analysis.
    König H; König HH; Konnopka A
    Epidemiol Psychiatr Sci; 2019 Apr; 29():e30. PubMed ID: 30947759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost of generalized anxiety disorder in primary care settings: results of the ANCORA study.
    Rovira J; Albarracin G; Salvador L; Rejas J; Sánchez-Iriso E; Cabasés JM
    Community Ment Health J; 2012 Jun; 48(3):372-83. PubMed ID: 22484993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review.
    Konnopka A; Leichsenring F; Leibing E; König HH
    J Affect Disord; 2009 Apr; 114(1-3):14-31. PubMed ID: 18768222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder.
    Ikic V; Belanger C; Bouchard S; Gosselin P; Langlois F; Labrecque J; Dugas MJ; Marchand A
    J Ment Health Policy Econ; 2017 Mar; 20(1):11-20. PubMed ID: 28418834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic costs of antidepressant use: a population-based study in Sweden.
    Beckman L; von Kobyletzki L; Svensson M
    J Ment Health Policy Econ; 2019 Dec; 22(4):125-130. PubMed ID: 32058977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs of depression in Catalonia (Spain).
    Salvador-Carulla L; Bendeck M; Fernández A; Alberti C; Sabes-Figuera R; Molina C; Knapp M
    J Affect Disord; 2011 Jul; 132(1-2):130-8. PubMed ID: 21402411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economic burden of mental disorders in China, 2005-2013: implications for health policy.
    Xu J; Wang J; Wimo A; Qiu C
    BMC Psychiatry; 2016 May; 16():137. PubMed ID: 27169936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden associated with alcohol dependence in a German primary care sample: a bottom-up study.
    Manthey J; Laramée P; Parrott S; Rehm J
    BMC Public Health; 2016 Aug; 16(1):906. PubMed ID: 27576562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human and economic burden of generalized anxiety disorder.
    Hoffman DL; Dukes EM; Wittchen HU
    Depress Anxiety; 2008; 25(1):72-90. PubMed ID: 17146763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-of-Illness in Rare Diseases.
    Linertová R; García-Pérez L; Gorostiza I
    Adv Exp Med Biol; 2017; 1031():283-297. PubMed ID: 29214579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-of-illness studies : a review of current methods.
    Akobundu E; Ju J; Blatt L; Mullins CD
    Pharmacoeconomics; 2006; 24(9):869-90. PubMed ID: 16942122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Economic Costs of Type 2 Diabetes: A Global Systematic Review.
    Seuring T; Archangelidi O; Suhrcke M
    Pharmacoeconomics; 2015 Aug; 33(8):811-31. PubMed ID: 25787932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.
    Bereza BG; Machado M; Einarson TR
    Clin Ther; 2009 Jun; 31(6):1279-308. PubMed ID: 19695395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Societal burden of clinically anxious youth referred for treatment: a cost-of-illness study.
    Bodden DH; Dirksen CD; Bögels SM
    J Abnorm Child Psychol; 2008 May; 36(4):487-97. PubMed ID: 18214667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of the association of anxiety with health care utilization and costs in people aged 65 years and older.
    Hohls JK; König HH; Raynik YI; Hajek A
    J Affect Disord; 2018 May; 232():163-176. PubMed ID: 29494900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic costs of anxiety disorders.
    DuPont RL; Rice DP; Miller LS; Shiraki SS; Rowland CR; Harwood HJ
    Anxiety; 1996; 2(4):167-72. PubMed ID: 9160618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical research practice datalink analysis of antidepressant treatment patterns and health care costs in generalized anxiety disorder.
    Chollet J; Saragoussi D; Clay E; François C
    Value Health; 2013 Dec; 16(8):1133-9. PubMed ID: 24326166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The costs of social anxiety disorder: the role of symptom severity and comorbidities.
    Stuhldreher N; Leibing E; Leichsenring F; Beutel ME; Herpertz S; Hoyer J; Konnopka A; Salzer S; Strauss B; Wiltink J; König HH
    J Affect Disord; 2014 Aug; 165():87-94. PubMed ID: 24882183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.